This study compared the carbon footprint of SC and IV administration using pertuzumab/trastuzumab as a case example. A Life Cycle Assessment was conducted to compare the environmental impacts of IV ...
In a National Institute for Health and Care Excellence (NICE) appraisal of a new drug (pertuzumab) in metastatic breast cancer, the appraisal consultation document (ACD) concluded that pertuzumab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback